Caricamento...
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
This year the medical community was pleasantly surprised by the results of the first large outcome trial that primarily examined the renal effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (CANA) in subjects with diabetes and impaired kidney function. The Evaluation of th...
Salvato in:
| Pubblicato in: | Nephrol Dial Transplant |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6993196/ https://ncbi.nlm.nih.gov/pubmed/32003836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfz264 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|